Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets rises 3.3% from a year ago

Total assets stood at $144.48M at the end of Q1 FY2026, up 3.3% from a year earlier and down 14.1% from the prior quarter. Over 3 fiscal years it compounded at +36.4% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +3.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$144.48M-14.1% QoQ
Last fiscal yearDec 2025
$168.2M+7.9% YoY
Year agoMar 2025
$139.93M+3.3% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.3%——
1 year+7.9%——
3-year CAGR+36.4%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
168.2M USD
Year-over-year change
+7.9%
4-year CAGR
+11.8%

Total Assets vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +3.3% is the 5th highest of 10, against a peer median of -19.4%.
  • Over three fiscal years its annual growth of +36.4% compares with a peer median of -18.4%.
CRBP Competitors
Total Assets for CRBP and competitors
Company Period Latest balance YoY 3-year CAGR
ALECAlector, Inc.Mar 2026$239.92M USD-41.2%-28.1%
MISTMilestone Pharmaceuticals Inc.Mar 2026$193.73M USD+213.1%+15.1%
PEPGPepGen Inc.Mar 2026$156.3M USD+22.7%-7.2%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$144.48M USD+3.3%+36.4%
MOLNMolecular Partners AGMar 2026CHF 87.4M CHF-38.1%-27.0%
FBRXForte Biosciences, Inc.Mar 2026$67.22M USD+41.6%+25.4%
IPHAInnate Pharma S.A.Dec 2025€62.69M EUR-43.6%-32.9%
RANIRani Therapeutics Holdings, Inc.Mar 2026$51.88M USD+115.0%-18.4%
CRDFCardiff Oncology, Inc.Mar 2026$49.17M USD-42.0%-18.9%
ELTXElicio Therapeutics, Inc.Mar 2026$22.69M USD-19.4%+4.5%
Peer median (excluding CRBP) —-19.4%-18.4%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.01M17M13.72M17.2M28.49M
Short-term Investments72.64M42.19M7.18M131.86M134.78M
Net Receivables00001.5M
Inventory00000
Other Current Assets192.48K192.48K192K3.91M1.52M
Total Current Assets100.2M60.18M23.55M152.98M166.95M
Property, Plant & Equipment (Net)7M5.5M4.04M2.52M1.24M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets523.81K632.77K690K385K0
Total Non-current Assets7.53M6.13M4.73M2.9M1.24M
Total Assets107.73M66.31M28.27M155.88M168.2M
Account Payables1.78M2.17M3.18M4.79M2.22M
Short-term Debt3.86M3.15M16.21M00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities133.71K36.87K39K2.28M2.86M
Total Current Liabilities17.01M12.64M31.89M11.82M20.69M
Long-term Debt15.64M15.98M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities22.21K22.21K44K00
Total Non-current Liabilities21.61M20.68M3.28M1.63M0
Total Liabilities38.62M33.32M35.18M13.45M20.69M
Common Stock12.52K41701K2K
Retained Earnings(349.73M)(392.08M)(436.68M)(476.89M)(555.43M)
Accumulated OCI(62.45K)(126.09K)(1K)35K(53K)
Other Stockholders Equity00(0)00
Minority Interest00000
Total Equity69.11M32.99M(6.91M)142.43M147.5M
Total Debt26.59M25.09M20.89M3.24M1.63M
Net Debt1.58M8.09M7.16M(13.96M)(26.86M)

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.